ArticleIntestinal Failure (New York, N.Y.)
The changing landscape of intestinal transplantation: Insights from the first quarter of the 21st century of Eurotransplant experience.
Article in Intestinal Failure (New York, N.Y.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Intestinal transplantation (ITx) remains one of the most complex procedures in solid organ transplantation. This study analyzes 25 years of Eurotransplant data to evaluate trends, outcomes, and prognostic factors. Methods: Retrospective analysis of all intestinal transplant candidates and recipients within Eurotransplant (2000-2024) was performed. Survival analysis used Kaplan-Meier curves and Cox regression models. Primary outcomes included transplantation rates, waitlist mortality, and post-transplant overall survival. Results: Among 303 patients, 215 received transplants and 88 remained non-transplanted. Transplanted patients were younger (37.7 ± 16.0 vs 42.3 ± 16.3 years, p = 0.030). Isolated intestinal transplantation comprised 46.0 % of procedures, while combinations with other organs accounted for 54.0 %. Cumulative transplantation incidence reached 70 % at four years, with significantly higher rates for liver-inclusive procedures (95 % vs 85 %, p = 0.00041). Waitlist mortality reached 40 % at four years, with trends toward higher mortality in adults versus pediatric patients. Post-transplant overall survival showed better univariate outcomes for transplants without liver components (HR=0.61, p = 0.034), though this difference disappeared after multivariable adjustment. Transplant year was independently associated with worse survival (HR=1.062, p = 0.005), reflecting changing selection criteria as non-transplant management improved. Annual transplant volume declined from 17 procedures (2007-2010) to 4 in 2023, despite stable donor reporting. Conclusions: Despite declining volumes, Eurotransplant ITx provides life-saving treatment with 70 % transplantation rates and outcomes comparable to international registries. The paradoxical survival trends reflect the field's success in expanding indications to more complex patients as parenteral nutrition advances. Strategic approaches including program consolidation and enhanced donor utilization could further optimize this essential therapeutic option for irreversible intestinal failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.